Future Price to Earnings: denalitherapeutics.com (DNLI)

Symbol and logo of brand Denali Therapeutics (DNLI)

Denali Therapeutics (DNLI) relies on cutting-edge R&D centers while outsourcing the production of neurological drugs to contract manufacturing organizations. The business's forward P/E clearly demonstrates the asset's real value relative to expected earnings, with the metric currently standing at 0.00. Distribution flexibility is ensured through the external management of clinical phases. Integration into the B2B environment with industry majors guarantees partner loyalty, despite strict FDA oversight.

DNLI - Denali Therapeutics Inc. Forward P/E Multiple over the range 07/04/2022 - 11/15/2026

Analytical breakdowns and data insights for company Denali Therapeutics Inc. (DNLI)

- company stock exchange capitalization indicators:
Fundamental valuation:Denali Therapeutics Inc. DNLI
Brand item of denalitherapeutics.com

The high competence of Denali Therapeutics (DNLI) management in CNS therapy and the transparency of deals with pharma behemoths establish a solid foundation for long-term capitalization growth. By analyzing this forward P/E chart, an investor determines the ratio of the current share price to expected earnings, allowing for a comparison of market expectations against actual drug development rates and the identification of asset undervaluation relative to the sector.

Key competitors

Forward P/E Multiple BIIB|NBIX - Projected Price to Earnings Ratio|Forward P/E Multiple RGC (Regencell Bioscience Ltd)|Market Cap to Projected Earnings axsome.com (AXSM)|ACADIA Pharmaceuticals Inc - Forward P/E Multiple|Projected Price to Earnings Ratio Xenon Pharmaceuticals Inc.|Viking Therapeutics (VKTX) - Future Price to Earnings|Supernus Corp - Future Price to Earnings Multiple|Projected Price to Earnings CPRX|Price to Future Earnings Ratio HRMY (Harmony Biosciences Holdings, Inc.)|Forward P/E Multiple BHVN|AMLX (Amylyx Pharmaceuticals Inc) - Future Price to Earnings Multiple|Forward P/E Multiple TRVI (Trevi Pharma)|PRAX (Praxis Corp) - Price to Expected Earnings Ratio|anavex.com - Forward P/E Multiple|Future Price to Earnings Multiple CBLL (CeriBell, Inc.)|PRTA: Forward P/E Multiple|Price to Future Earnings Ratio ALEC|ANNX (Annexon Biosciences Inc.) - Forward P/E Multiple|omeros.com - Price to Expected Earnings Ratio|Future Price to Earnings Neurogene (NGNE)|Market Cap to Projected Earnings AC Immune SA|Forward P/E Multiple VYGR (voyagertherapeutics.com)|Forward P/E Multiple Neumora NMRA|Scilex Holding - Forward P/E Multiple|Projected Price to Earnings Ratio Tevogen Bio Inc.|Alpha Cognition (ACOG) - Future Price to Earnings|cogrx.com (CGTX) - Forward P/E Multiple|Future Price to Earnings Inhibikase Therapeutics|Cassava (SAVA) - Market Cap to Projected Earnings|Future Price to Earnings Assertio Therapeutics (ASRT)|Market Cap to Projected Earnings Coya|Vistagen - Projected Price to Earnings|Future Price to Earnings Multiple OVID|Acumen Pharmaceuticals Inc. - Forward P/E Multiple|Projected Price to Earnings Ratio CervoMed Inc|ATHE: Forward P/E Multiple|Projected Price to Earnings Clene Nanomedicine|Future Price to Earnings PepGen Corp|Jupiter Neurosciences (JUNS) - Market Cap to Projected Earnings|Future Price to Earnings Relmada Therapeutics, Inc. (RLMD)|ANVS - Projected Price to Earnings Ratio|gracetx.com - Projected Price to Earnings|AIFF: Price to Future Earnings Ratio|Klotho Neurosciences - Forward P/E Multiple|NRSN (NeuroSense Therapeutics Ltd.) - Price to Future Earnings Ratio|Reviva Pharmaceuticals (RVPH) - Future Price to Earnings|MTVA (MetaVia Inc.) - Future Price to Earnings|Future Price to Earnings NeurAxis, Inc|Future Price to Earnings HSDT|Forward P/E Multiple PASG|Market Cap to Projected Earnings Neuphoria Therapeutics, Inc.|minervaneurosciences.com - Projected Price to Earnings|Forward P/E Multiple Athira ATHA|Addex Therapeutics - Forward P/E Multiple|ALZN - Forward P/E Multiple|Cyclerion (CYCN) - Future Price to Earnings|Protagenic (PTIX) - Forward P/E Multiple|Future Price to Earnings Pasithea|Price to Future Earnings Ratio CRGT (Cortigent)|Future Price to Earnings Avenue Therapeutics (ATXI)|BCLI - Projected Price to Earnings Ratio|Forward P/E Multiple CARA (Cara Therapeutics Inc)|CHRO - Projected Price to Earnings|ELYM: Projected Price to Earnings|Market Cap to Projected Earnings Intra-Cellular Therapies, Inc. ITCI|Longboard Pharma (LBPH) - Future Price to Earnings|Marinus - Future Price to Earnings Multiple|Future Price to Earnings NKGen Biotech Inc|NRBO: Future Price to Earnings Multiple|Projected Price to Earnings SAGE (Sage Therapeutics, Inc.)|Market Cap to Projected Earnings Neurotrope|Future Price to Earnings Trevena, Inc. TRVN|Vigil Neuroscience (VIGL) - Projected Price to Earnings Ratio|WENA: Projected Price to Earnings|Future Price to Earnings Multiple CERE (Cerevel Therapeutics)